Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review emphasizes the importance of accurately distinguishing between diffuse alopecia areata and telogen effluvium in dermatological practice due to differing treatment implications and long-term patient expectations, but reports no new clinical results.

This study found that alopecia areata patients with eosinophilia were more likely to have severe hair loss, atopia, and nail abnormalities compared to those without eosinophilia.

This study compared oral tofacitinib and methotrexate in treating moderate-to-severe alopecia areata, finding that tofacitinib was more effective at reducing SALT scores and improving scalp hair assessment PRO scores, though both treatments reduced psychological distress similarly without serious adverse effects.

In this retrospective analysis, the authors reported that off-label tofacitinib treatment in 35 alopecia areata patients demonstrated safety, with no serious adverse events, and effectiveness, with 83.9% showing significant scalp regrowth and 32.3% achieving near total or total regrowth.

This report describes a case of acute localised exanthematous pustulosis in a 19-year-old boy after using amoxicillin-clavulanic acid, with new dermoscopic features identified.

In this report, a 14-year-old female with stubborn alopecia areata was successfully treated with oral tofacitinib, indicating its potential effectiveness for severe cases.

The study concluded that the Exprecell™ device for preparing anticoagulant-free f-PRF increases volume yield and simplifies the process while maintaining biological activity comparable to conventional methods, suggesting potential clinical utility.

This case report describes a patient with frontal fibrosing alopecia experiencing significant hair regrowth and reversal of cutaneous atrophy after treatment with the 5α-reductase inhibitor finasteride.

This study presents a validated questionnaire, the FFA-QLI, which effectively assesses and differentiates the quality of life impact among patients with frontal fibrosing alopecia, showing greater sensitivity in identifying severe cases than the DLQI.

In this study, both fractional carbon dioxide laser therapy and cryotherapy were found to be effective and safe for treating patchy alopecia areata, showing similar efficacy in improving hair growth compared to untreated control patches.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

This paper reviews the challenges of treating alopecia areata affecting eyelashes and discusses the risks associated with traditional therapies; it reports no new clinical results.

This study suggests that allergens like linalool found in personal care products may contribute to the pathobiology of frontal fibrosing alopecia by affecting immune responses and stem cell function in hair follicles.

This study found that Egyptian women with frontal fibrosing alopecia had lower serum PPARγ levels and a higher occurrence of PPARG gene polymorphism compared to healthy controls, suggesting a potential role for PPARγ in the condition's development.

This pharmacovigilance study found strong disproportionality signals suggesting an association between finasteride and Peyronie's disease-related clinical features, but the evidence does not confirm a causal link.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

This study found that FDA-cleared devices for preparing platelet-rich plasma showed inconsistent product quality, with variable platelet counts and inadequate quality control performance, suggesting clinical improvement may not rely on platelet concentration.

In this retrospective study, oral tofacitinib treatment for at least 6 months improved scalp hair loss in 69.1% of alopecia areata patients, with patchy AA cases responding better compared to other subtypes, and no significant adverse effects were reported.

This study found that fig leaf extract significantly downregulated inflammatory and androgenic gene expression in vitro, suggesting potential topical benefits for certain skin disorders.

This study found that palmitoylethanolamide may stimulate allopregnanolone synthesis and reduce oxidative stress in astrocytes through PPAR-α activation, suggesting a neuroprotective role.

This article hypothesizes that apremilast, a phosphodiesterase 4 inhibitor, could be a targeted treatment for alopecia areata due to its ability to suppress interferon-gamma production, but reports no new clinical results.

This study found that key amino acids lost from hair due to weathering can be successfully reintroduced through cosmetic treatments, improving hair strength and aesthetics.

This study found that among adults with severe alopecia areata, alopecia totalis, or alopecia universalis, oral tofacitinib was more effective than methotrexate in reducing hair loss over a 12-week period, though long-term safety and efficacy remain unestablished.

This study's simulations suggest that replenishing free 18‐MEA could restore damaged hair surface properties, highlighting the importance of optimal fatty acid spacing for maintaining hair integrity.

This study found that tenofovir alafenamide fumarate (TAF) is an effective and safer alternative to tenofovir disoproxil fumarate (TDF) for chronic hepatitis B, with fewer long-term side effects like nephrotoxicity and decreased bone density.

This article discusses the crucial role of root hairs in water and nutrient uptake from soil and reports no new findings.

This study found that N-acetyl-GED may protect and partially rescue human hair follicles from experimentally-induced epithelial-mesenchymal transition ex vivo, suggesting its potential in treating scarring alopecias like lichen planopilaris.

This study found that Fibroblast growth factor-9 (FGF-9) accelerates epithelial invagination in engineered ectodermal organs and suggests its potential role in organogenesis and regeneration research.